spacer
The Healthcare Sales & Marketing Network celebrates 28 years serving the medical sales & marketing community.Connecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product LinesConnecting Medical Independent Sales Reps and Distributors with Manufacturers and New Product Lines

Searching News Database:  porphyria 

 HSMN NewsFeed - 2 Sep 2021
Disc Medicine Announces $90 Million Series B Financing to Advance Portfolio of Clinical-Stage Therapies for Hematologic Diseases
Biopharmaceuticals Venture Capital
 HSMN NewsFeed - 5 Jul 2017
Recordati Rare Diseases Introduces New PANHEMATIN(R) (Hemin for Injection) Dosage Strength for Treatment of Acute Intermittent Porphyria (AIP)
Biopharmaceuticals Product Launch
 HSMN NewsFeed - 6 Jul 2016
US FDA pathway opens to SCENESSE(R) following Fast Track designation for treatment of EPP
Biopharmaceuticals FDA
 HSMN NewsFeed - 2 May 2016
Enhanced Cystoscopy including Blue Light Cystoscopy with Cysview(R)/Hexvix(R) is Recommended in the New AUA/SUO Bladder Cancer Guideline
Biopharmaceuticals Diagnostics Urology Oncology
 HSMN NewsFeed - 2 Jul 2014
Alnylam Elects Amy Schulman to its Board of Directors
Biopharmaceuticals Personnel
 HSMN NewsFeed - 13 Jan 2014
Alnylam and Genzyme Form Transformational Alliance for RNAi Therapeutics as Genetic Medicines
Biopharmaceuticals Licensing
 HSMN NewsFeed - 2 Nov 2012
uniQure's Glybera(R) First Gene Therapy Approved by European Commission
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 20 Jul 2012
First Gene Therapy in Western World Receives Positive Opinion in Europe from CHMP
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 30 Jan 2012
Amsterdam Molecular Therapeutics Announces European Commission Delays Decision on Glybera(R) Marketing Authorisation and Requests Further Information From the CHMP
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 4 Jan 2012
Amsterdam Molecular Therapeutics Receives US Orphan Designation for Hemophilia B Gene Therapy
Biopharmaceuticals FDA
 HSMN NewsFeed - 16 Nov 2011
Amsterdam Molecular Therapeutics Receives Orphan Designation in the European Union for Hemophilia B Gene Therapy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 8 Jul 2011
Amsterdam Molecular Therapeutics Files Glybera(R) European Marketing Application for Re-examination
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 24 Jun 2011
Amsterdam Molecular Therapeutics Receives Opinion on Glybera(R) Marketing Authorisation Application
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 22 Jun 2010
QLT Announces Final Results From Its RADICAL Study Evaluating Verteporfin PDT (Visudyne(R)) Combination Therapy in Exudative AMD
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 1 Jun 2010
Cysview(TM) (Hexaminolevulinate HCL) Approved by the FDA for Cystoscopic Detection of Papillary Bladder Cancer
Diagnostics Oncology FDA
 HSMN NewsFeed - 9 Dec 2009
6-month results from EVEREST study evaluating Visudyne(R) therapy in patients with polypoidal choroidal vasculopathy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 2 Dec 2009
AMT Announces Management Changes in Light of Refocused Strategy
Biopharmaceuticals Personnel
 HSMN NewsFeed - 15 Jun 2009
QLT announces 12-month results from Novartis sponsored MONT BLANC study evaluating standard-fluence Visudyne(R) combination therapy
Biopharmaceuticals Ophthalmology
 HSMN NewsFeed - 13 Jun 2007
Bradley Pharmaceuticals Announces Launch of Elestrin(TM)
Biopharmaceuticals
 HSMN NewsFeed - 12 Mar 2007
New European Approval for Xyrem(R) Provides Significant Advance in the Treatment of Narcolepsy
Biopharmaceuticals Regulatory
 HSMN NewsFeed - 6 Sep 2006
OVATION and Cardinal Health Announce FDA Approval Letter for Manufacturing of Biologic Therapy To Treat Rare Genetic Disorder
Biopharmaceuticals FDA
Return to NewsFeed  

 Additional items found! 4

Members: click here for search results from The HSMN Archive (password required)
Members Archive contains 4 additional stories matching:
porphyria
(Password required)
FindReps - Find Great Medical Independent Sales Reps without recruiter fees.
FindReps - available on the Apple App Store for iPhone and iPad.